Back to News
Market Impact: 0.2
Galderma's Nemluvio Shows Sustained Benefits In Inflammatory Skin Diseases Through 3 Years
Source: Nasdaq
Healthcare & Biotech
Galderma presented new three-year data from the ARCADIA long-term extension study showing sustained improvements with Nemluvio (nemolizumab) in patients with atopic dermatitis. The report provided no numerical effect sizes or additional study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
GALD0.55
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook
- William Blair downgrades Alignment Healthcare stock rating on cost pressures
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund